Skip to main content
Equibles
GRAL logo

GRAL · GRAIL, Inc. · Earnings Call Transcripts & Audio

Track GRAL — free

Use GRAL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GRAL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$140.58 +4.01 (+2.94%)
Russell 2000 member Rebalance outlook locked
Market Cap
$5.67B
Shares
44.67M
Volume · Sep 30 1.92M Avg daily vol (3M) 859.42K

GRAIL, Inc. Earnings Call Transcripts

Quarterly earnings calls for GRAIL, Inc. (GRAL), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲42.6% $31.97M −$1.59B '24 Q2 24-08-13 ▲38.3% $28.65M −$125.69M '24 Q3 24-11-12 · $38.25M −$97.07M '24 Q4 25-02-20 ▲19.1% $31.84M −$106.21M '25 Q1 25-05-13 ▲11.2% $35.54M −$113.98M '25 Q2 25-08-12 ▲26.3% $36.19M −$88.98M '25 Q3 25-10-16 ▲14% $43.60M −$99.18M '25 Q4 26-02-19 ▲28.1% $40.78M −$93.19M '26 Q1 26-05-05 LATEST ▲25.7% $44.69M −$110.25M '26 Q2 26-08-05
Conference
Investor event
2026-09-14
GRAIL, Inc. (GRAL) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-11
GRAIL, Inc. (GRAL) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
Confident tone Regulatory path (FDA approval, adcom, Medicare) Samsung partnership and international expansion Payer and employer coverage partnerships
Revenue
$44.69M
▲ 25.7% YoY
Diluted EPS
$-2.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
GRAIL, Inc. (GRAL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
Positive tone FDA PMA review and approval timeline NHS-Galleri and PATHFINDER 2 clinical data / ASCO 2026 guidance and conservatism
Revenue
$40.78M
▲ 28.1% YoY
Diluted EPS
$-2.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
Positive tone NHS-Galleri trial results Commercial performance of Galleri FDA PMA submission
Revenue
$43.60M*
▲ 14% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-16
GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript
Confident tone Commercial volume and revenue growth Clinical evidence - SIMPLIFY Clinical evidence - PATHFINDER II
Revenue
$36.19M
▲ 26.3% YoY
Diluted EPS
$-2.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript
Confident tone Galleri commercial volume growth PATHFINDER 2 clinical study results International expansion and tech transfer
Revenue
$35.54M
▲ 11.2% YoY
Diluted EPS
$-3.18
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript
Positive tone NHS-Galleri Trial Results NHS Commercialization Partnership Test Performance and Real World Evidence
Revenue
$31.84M
▲ 19.1% YoY
Diluted EPS
$-3.10
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
Positive tone Galleri commercial momentum and test volume Quest and TRICARE distribution/coverage expansion Cash burn reduction and financial runway
Revenue
$38.25M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
GRAIL, Inc. (GRAL) Q3 2024 Earnings Call Transcript
Positive tone Galleri test demand and commercial performance FDA approval pathway and registrational studies Reimbursement strategy and legislation
Revenue
$28.65M
▲ 38.3% YoY
Diluted EPS
$-3.94
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
GRAIL, Inc. (GRAL) Q2 2024 Earnings Call Transcript
Positive tone Galleri commercial performance and demand FDA PMA submission and registrational studies Corporate restructuring and cost reduction
Revenue
$31.97M
▲ 42.6% YoY
Diluted EPS
$-51.06
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts CIK 1699031 CUSIP 384747101 13F (30d) 14 filings 13 filers Visit website Investor relations